News

The monoclonal antibody will be engineered by GBI’s collaborative partner, and then GBI will evaluate the cell lines, select the highest producer and manufacture the monoclonal antibody for

The Phase 2 ZP-204 study is a five arm dose escalation study in which up to 12 women with diagnosed endometriosis or uterine fibroids were randomized to 1,

VelQuest is specialized in paperless lab execution systems supporting current Good Manufacturing Practices (cGMP) for FDA-regulated industries including pharmaceuticals and biotechnology organizations. Following the acquisition, Accelrys’ software portfolio

Quture’s new science and technology will introduce electronic performance measurement to empower hospitals and surgery centers to measure clinical performance on the InterSystems Corporation technology platform. Rural and

Tivozanib is a potent, selective and continuous inhibitor of all three vascular endothelial growth factor (VEGF) receptors that are designed to optimize VEGF blockade while minimizing off-target toxicities.

Lynovex is the company’s novel dual mucolytic-antibacterial drug for the treatment of cystic fibrosis (CF). According to the company, Lynovex (Cysteamine) is the first drug candidate with a

The GlobalMed i8500 Series Mobile Telemedicine Carts powered by HP combine the power of the HP Z210 SFF(Small Form Factor) Workstations with HP L2105 Widescreen LCD Touchscreen monitors

The biopharmaceuticals are produced utilizing Ossianix’s Osss proprietary single domain antibody platform modeled on the shark vNAR structure. Lundbeck will retain the right to negotiate for certain products

The FDA approved Onfi for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients two years and older. Onfi is an oral anti-epileptic drug (AED) of